by valeo-adm | Jun 7, 2023 | News Release
MONTREAL, QUEBEC , June 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2023 on...
by valeo-adm | May 25, 2023 | Communiqué de presse
Les revenus du T2-23 devraient dépasser 13,5 millions $ La perte de BAIIA ajusté du T2-23 devrait être inférieure à 2,0 millions $ Les dépenses d’exploitation du T2-23 resteront conformes à celles des trimestres précédents Les revenus trimestriels...
by valeo-adm | May 25, 2023 | News Release
Q2-23 revenues to exceed $13.5 million Q2-23 adjusted EBITDA loss to decrease below $2.0 million Q2-23 operating expenses to remain in line with prior quarters ENERZAIR® and ATECTURA® quarterly revenues grow 270% over prior year MONTREAL, QUEBEC , May 25, 2023 –...
by valeo-adm | Apr 28, 2023 | Communiqué de presse
MONTRÉAL (QUÉBEC), le 28 avril 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd’hui les résultats des propositions soumises aux...
by valeo-adm | Apr 28, 2023 | News Release
MONTREAL, QUEBEC , April 28, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced the results of the proposals submitted to shareholders at its annual meeting of shareholders held on...
